As organizations face talent shortages, shifting culture demands, generational transitions and heightened stakeholder ...

One of Cincinnati's most active developers will be doing something new when it builds a $40 million apartment project in ...

Eti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after ≥2 prior lines of therapyIn vivo data suggest IL-2 may further enhance response ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MAPT, the company’s investigational RNA interference (RNAi) ...

December 8, 2025) - Contango ORE, Inc. (NYSE American: CTGO) ("Contango" or the "Company") and Dolly Varden Si ...

Total consideration upon satisfaction of closing conditions will be approximately $4 million in ICG equity Up to US$5 million in additional ...